{"nctId":"NCT01146860","briefTitle":"Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis","startDateStruct":{"date":"2010-01"},"conditions":["Acute Rhinosinusitis"],"count":386,"armGroups":[{"label":"BNO 1016","type":"EXPERIMENTAL","interventionNames":["Drug: BNO 1016"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"BNO 1016","otherNames":["Sinupret extract"]},{"name":"Placebo","otherNames":["Placebo to BNO 1016"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nDiagnosis of acute rhinosinusitis\n\n* characterized by a major symptom score (MSS) ≥ 8 and ≤ 12 points (minimum 0, maximum 15 points)\n* individual score for facial pain/pressure ≥ 1 (mild) and ≤ 2 (moderate)\n* confirmed by ultrasonography of paranasal sinuses\n* with presence of symptoms ≤ 3 days prior to inclusion\n\nExclusion Criteria:\n\n* Chronic rhinosinusitis\n* Polyposis nasi\n* Anatomical deviations of the nasal septum that significantly impair nasal and paranasal ventilation/airflow\n* Acute symptoms of a known allergic rhinitis\n* Patients with asthma who have a history of exacerbations within 30 days prior to study inclusion\n* Signs or symptoms of fulminant bacterial sinusitis\n* Odontogenic sinusitis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Major Symptom Score (MSS) Assessed by the Investigator","description":"MSS: sum of the 5 main rhinosinusitis symptoms which are: rhinorrhea (anterior discharge), postnasal drip, nasal congestion, headache, facial pain/pressure.\n\nEach symptom is individually evaluated using the following 4-point rating scale (scoring system): 0 = none/not present, 1 = mild, 2 = moderate, 3 = severe.\n\nThus the MSS ranges from a minimum of 0 to a maximum of 15 score points.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.38","spread":"0.18"},{"groupId":"OG001","value":"3.41","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"SNOT 20 Symptom Scores","description":"Sino-Nasal Outcome Test (SNOT 20): 20 item questionnaire to assess the symptoms and emotional and social consequences of rhinosinusitis. The symptoms are assessed by the patient using a 6-point rating scale: 0 = not present / no problem, 1 = very mild problem, 2 = mild or slight problem, 3 = moderate problem, 4 = severe problem, 5 = problem as \"bad as it can be\".\n\nrange: 0 to 100","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.02","spread":"12.72"},{"groupId":"OG001","value":"15.76","spread":"16.26"}]}]}]},{"type":"SECONDARY","title":"Major Symptom Score Assessed by the Patient","description":"MSS: sum of the 5 main rhinosinusitis symptoms which are: rhinorrhea (anterior discharge), postnasal drip, nasal congestion, headache, facial pain/pressure.\n\nEach symptom is individually evaluated using the following 4-point rating scale (scoring system): 0 = none/not present, 1 = mild, 2 = moderate, 3 = severe.\n\nThus the MSS ranges from a minimum of 0 to a maximum of 15 score points.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.62","spread":"0.21"},{"groupId":"OG001","value":"3.48","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Classified as Responders by the Investigator on a 4-point Rating Scale","description":"General assessment of efficacy using a 4-point rating scale (symptoms healed, improved, unchanged, deteriorated). Patients whose symptoms are improved or healed will be classified as \"responders\" to treatment. Patients whose symptoms are unchanged or deteriorated as classified as \"non-responders\".","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.2","spread":null},{"groupId":"OG001","value":"87.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Ultrasonography of Paranasal Sinuses","description":"Percentage of patients with signs of acute rhinosinusitis in ultrasonography of paranasal sinuses will be evaluated. Ultrasonography scans will be visually evaluated by the investigator for signs of rhinosinusitis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.8","spread":null},{"groupId":"OG001","value":"38.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":194},"commonTop":["Diarrhoea","Gastroenteritis","Toothache","Back pain","Dizziness"]}}}